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The envelope glycoprotein (Env)2 of human immunodeficiency virus-type 1 (HIV-1) is composed of gp120 and gp41
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subunits arranged as a trimer of heterodimers in the viral membrane (1). It is formed through trimerization in the endoplasmic
reticulum of precursor protein gp160, which is subsequently
cleaved into a surface (gp120) and transmembrane (gp41) subunit
that remain noncovalently associated. The three gp120 subunits
form a canopy that cradles a trimeric gp41 core and locks the
transmembrane protein in a metastable conformation (2–4).
Trimerization is stabilized through gp120–gp120 interactions
involving the V1/V2 and V3 variable loops at the apex of the complex and through a coiled coil formed by part of an N-terminal
heptad repeat (N-HR) in the gp41 ectodomain (5–7).
Env undergoes receptor-triggered conformational changes
to promote HIV-1 entry through membrane fusion (8 –10). The
gp120 subunits interact with cellular CD4, altering the Env apex
to release constraints on the V3 loops. The released V3 loop and
an additional newly formed gp120 element (bridging sheet) can
now interact with a chemokine receptor, typically CCR5 or
CXCR4 (collectively referred to as the coreceptor) (11–15).
Receptor interactions also alter the gp120/gp41 interface and
coordinate a complex series of structural changes in the transmembrane subunit (8, 9). First, each gp41 extends to insert its
N-terminal fusion peptide segment into the target cell membrane. During this intermediate state (denoted the prehairpin
intermediate or PHI), the N-HR coiled coil and an additional
heptad repeat segment at the C terminus of the gp41 ectodomain (C-HR) become transiently exposed to the extracellular
environment (16 –20). Driven by a strong affinity for one
another, the N-HR coiled coil associates with the three C-HR
domains to form a compact trimer-of-hairpins (TOH) (21, 22).
Collapse into the TOH juxtaposes the fusion peptides, transmembrane regions, and their associated membranes in a manner required for viral membrane fusion (10).
Molecules that block Env interactions with cellular receptors
or disrupt Env conformational changes can effectively inhibit
HIV-1 entry (23). Two classes of such molecules are currently
used in the clinic. The first, denoted coreceptor antagonists
(CoRAs), binds to the extracellular loops and transmembrane
helices of CXCR4 or CCR5, blocking their interaction with the
V3 loop of gp120 (24). The second, denoted fusion inhibitors
(FIs), binds to the gp41 N-HR coiled coil or C-HR segments,
blocking their ability to form the TOH (25–30). The clinically
approved drugs maraviroc (CoRA) and enfuvirtide (FI, also
denoted T20) are currently employed as second line therapy
diate; TOH, trimer-of-hairpins; CoRA, chemokine receptor antagonist; FI,
fusion inhibitor; PBMC, peripheral blood mononuclear cell.
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The homotrimeric HIV-1 envelope glycoprotein (Env) undergoes receptor-triggered structural changes that mediate viral
entry through membrane fusion. This process is inhibited by
chemokine receptor antagonists (CoRAs) that block Env–
receptor interactions and by fusion inhibitors (FIs) that disrupt
Env conformational transitions. Synergy between CoRAs and
FIs has been attributed to a CoRA-dependent decrease in the
rate of viral membrane fusion that extends the lifetime of the
intermediate state targeted by FIs. Here, we demonstrated that
the magnitude of CoRA/FI synergy unexpectedly depends on
FI-binding affinity and the stoichiometry of chemokine receptor
binding to trimeric Env. For C-peptide FIs (clinically represented by enfuvirtide), synergy waned as binding strength
decreased until inhibitor combinations behaved additively.
Curiously, this affinity dependence on synergy was absent for
5-Helix-type FIs. We linked this complex behavior to the CoRA
dependence of Env deactivation following FI binding. For both
FI classes, reducing chemokine receptor levels on target cells or
eliminating competent chemokine receptor-binding sites on
Env trimers resulted in a loss of synergistic activity. These data
imply that the stoichiometry required for CoRA/FI synergy
exceeds that required for HIV-1 entry. Our analysis suggests two
distinct roles for chemokine receptor binding, one to trigger
formation of the FI-sensitive intermediate state and another to
facilitate subsequent conformational transitions. Together, our
results could explain the wide variety of previously reported
activities for CoRA/FI combinations. These findings also have
implications for the combined use of CoRAs and FIs in antiviral
therapies and point to a multifaceted role for chemokine receptor binding in promoting HIV-1 entry.
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Figure 1. Combinatorial activities of CoRA maraviroc and FIs T20 and 5-Helix against EnvJR-FL. A, maraviroc titration of HIV-1 infection in the absence of
FIs. Data have been normalized to the infection level in the absence of inhibitor. Data at maraviroc concentrations 0.5 (red), 1 (green), 2 (dark blue), and 4 nM
(cyan) have been highlighted as these concentrations were used for combinatorial studies. The measured IC50 value is 0.45 ⫾ 0.15 nM. B, schematic of gp41
depicting the relative positions of the fusion peptide (FP), N-HR, C-HR, and transmembrane (TM) segments of the ectodomain. Binding sites for T20 and 5-Helix
are designated. C, titration of T20 in the absence (black) and presence of maraviroc (colored as in A). Data have been normalized to the infection level in the
absence of either entry inhibitor. D, T20 titrations shown in C renormalized to the level of infection in the absence of T20 and the presence of maraviroc (if any).
E, plot of IC50 for T20 inhibition as a function of maraviroc concentration. IC50 values were determined from the titration curves shown in D. F–H, data for 5-Helix
inhibition displayed as described in C–E. Data points and error bars represent the mean ⫾ S.E. of three or more independent experiments. Titrations have been
fit (solid lines) with a simple dose-response equation to extract IC50 values (see Equation 1).

and used when traditional highly active antiretroviral therapy
(HAART) becomes ineffective (31–34).
Based on their mechanisms of action, CoRAs and FIs should
display synergistic activity when used in combination. Because
the gp41 N-HR and C-HR are only transiently exposed during
the PHI, FI potency depends on kinetics of inhibitor binding
and Env dynamics (16, 17, 19, 35–39). An important determinant of FI activity is the lifetime of the PHI, a property that
critically depends on Env interactions with chemokine receptors. Reducing either coreceptor levels on target cells or their
binding affinity for gp120 decreases the rate of Env-mediated
membrane fusion, prolonging the lifetime of the PHI (19, 35,
38 – 42). Because FIs have more time to bind gp41 during this
prolonged PHI, their potency is enhanced. Theoretically,
CoRAs should have the same functional effect as reducing coreceptor levels on target cells.
Surprisingly, studies of CoRA/FI combinations have produced inconsistent results. Although some reports have shown
strong synergy between FIs and CoRAs (or coreceptor-binding
proteins such as RANTES (regulated on activation normal T
cell expressed and secreted) or monoclonal antibodies) (43–
45), a number of studies have revealed only weak synergy or
additivity between these two inhibitor classes (31, 45, 46). In
one study exploring combinations of CoRA SCH-C and T20 on

activated peripheral blood mononuclear cells (PBMCs), three
of six CCR5-tropic clinical HIV-1 isolates showed little or no
synergy at all inhibitor concentrations, whereas the others
showed strongly dose-dependent synergy (47). Here, we investigated the origins of this variability by exploring the inhibitory
properties of different CoRA/FI combinations against different
Env variants. Our findings revealed that the mechanism of synergy is more complex than originally postulated. We showed
that the degree of CoRA/FI synergy strongly depends on FIbinding affinity and on coreceptor-Env binding stoichiometry.
The results have implications for the effectiveness of clinical
therapies involving CoRA/FI combinations and for the role of
coreceptor binding in coordinating Env structural changes during HIV-1 entry.

Results
Measurement of synergy between FIs and CoRAs
There are a number of strategies to quantify the synergistic,
additive, or antagonistic properties of inhibitor combinations
(48 –50). In this study, we focused specifically on the impact of
CoRAs on the inhibitory potency of FIs. Our strategy is outlined
in Fig. 1, A and C–E, on data obtained using inhibitors maraviroc and T20. HIV-1 pseudotyped with primary isolate EnvJR-FL
J. Biol. Chem. (2017) 292(40) 16498 –16510
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P entry ⫽

1
[inhibitor]
1⫹
IC50 (inhibitor)

(Eq. 1)

Dependence of C-peptide FI/CoRA synergy on C-peptidebinding affinity

For inhibitors that do not compete for the same site, additive
combinatorial activity can be modeled as the product of individual entry probabilities as shown in Equation 2.
P entry ⫽

1
1
䡠
关CoRA兴
关FI兴
1⫹
1 ⫹
IC50 共CoRA兲
IC50 (FI)

(Eq. 2)

Under additive interactions, the presence of CoRA will only
impact the scale of FI titrations but not their IC50 values. Hence,
renormalized FI titrations (e.g. Fig. 1D) should overlap, and the
FI IC50 versus CoRA concentration plot (e.g. Fig. 1E) should be
horizontal. However, if the two inhibitors interact synergistically, then the IC50 values of the normalized FI titrations will be
less in the presence than in the absence of CoRA (as observed).
Conversely, if the two inhibitors interacted antagonistically,
then the IC50 values of the normalized FI titrations will be
greater in the presence than in the absence of CoRA. The analysis employed here shares a common logic with the calculation
of combination indices developed by Chou and Talalay and
routinely used to quantify drug combinatorial properties (48).
Expanding the product in Equation 2 yields Equation 3.
P entry ⫽

1
[CoRA]
[FI]
[CoRA] 䡠 [FI]
1⫹
⫹
⫹
IC50 (CoRA) IC50 (FI) IC50 (CoRA) 䡠 IC50 (FI)
(Eq. 3)

The last three terms of the denominator are equivalent to the
value of the combination index at 50% inhibition for mutually
nonexclusive inhibitors.
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FI T20 is an example of a C-peptide, so named because they
are derived from the gp41 C-HR segment. C-peptides block
entry by binding to the gp41 N-HR coiled coil exposed in the
PHI (17, 20, 27, 51). We next asked whether FIs that work in a
complementary manner by targeting gp41 C-HR region would
show similar synergistic activity with CoRAs. We used 5-Helix
(5HWT), an engineered protein containing three N-HR segments and two C-HR segments alternately connected through
short Gly/Ser linkers (28). When properly folded, 5HWT
exposes a single high-affinity site that binds the gp41 C-HR
region during the PHI. Like T20, 5HWT showed significantly
improved inhibitory activity in the presence of maraviroc (Fig.
1, F–H). However, we did observe considerable differences
between the two FIs. First, the magnitude of synergy for 5HWT
was substantially less, with IC50 falling from 83 to 15 nM (a
5.5-fold change) when the maraviroc concentration was raised
from 0 to 4 nM. Second, T20 activity was much more sensitive to
maraviroc concentration than 5HWT activity; the impact on
T20 potency appeared to saturate at ⬃1 nM maraviroc, whereas
the impact on 5HWT potency did not saturate in the studied
maraviroc concentration range. The differences likely reflect an
asymmetry in exposure of the gp41 N-HR and C-HR regions
and/or differences in the determinants of potency for FIs that
target these sites (36, 38).

As a potential source of variability in reported inhibitor combination studies, we asked whether the properties of CoRA/FI
synergy were altered in the presence of Env mutations that disrupt FI-binding affinity. In these experiments, we used HIV-1
pseudotyped with CXCR4-tropic EnvHXB2, U87-CD4-CXCR4
target cells, and CoRA AMD3100. The FI was C37, a well-characterized C-peptide with a binding site that overlaps that for
T20 (38, 52). As with maraviroc/T20 combinations in Fig. 1,
C37 IC50 decreased from 2.8 to 0.37 nM (7.4-fold) as AMD3100
concentration was increased from 0 to 100 nM (Fig. 2C). We
next analyzed a mutant Env variant containing the V549E substitution known to disrupt C37-binding affinity by 5000-fold
and reduce C37 inhibitory potency by 100-fold (Table 1) (38,
53). The mutation did not alter the potency of AMD3100 (IC50
⬃26 nM), implying that the V549E substitution did not affect
Env utilization of the coreceptor (Fig. 2B). By contrast, the
mutation ablated synergistic activity between AMD3100 and
C37 observed for wild-type Env (Fig. 2, C and D); C37 IC50
values for the V549E Env variant in the presence of 0 and 100 nM
AMD3100 were essentially identical (⬃200 nM). The data suggested that AMD3100/C37 combinatorial activity was influenced by FI-binding affinity.
To confirm the importance of binding affinity on the magnitude of CoRA/FI synergy, we studied the combinatorial activities of AMD3100 and mutant C37 variants with altered binding
affinity. We first explored the inhibitory properties of two
mutant C37 variants with lower binding affinities, C37W628A
(50-fold lower affinity) and C37N656D (4000-fold lower) (38).
Consistent with their reduced binding affinities, the mutant
C37 variants displayed lower potency against wild-type Env
(Table 1 and Fig. 3A). Moreover, they also showed significantly

Downloaded from http://www.jbc.org/ at Thomas Jefferson University on October 25, 2017

was utilized to infect U87-CD4-CCR5 target cells. The IC50
(IC50 indicates 50% inhibitory concentration) value for maraviroc in the absence of FI was first determined through careful
titrations to be 0.45 nM (Fig. 1A). FI titrations were subsequently performed in the absence or presence of maraviroc at
various concentrations (0.5, 1, and 2 nM, Fig. 1C). All titrations
were fit to a simple dose–response relationship (Langmuir
equation, see below) to extract IC50 values. To best appreciate
the impact of maraviroc on FI potency, we renormalized each FI
titration to the level of infection obtained in the absence of FI
(Fig. 1D). The leftward shift of these renormalized curves in
the presence of CoRA indicates an increase in T20 potency
with increasing maraviroc concentrations. T20 IC50 values
decreased from 35 to 2 nM as the maraviroc concentration was
raised from 0 to 2 nM, reflecting a 17-fold improvement in FI
potency (Fig. 1E).
The decrease in the FI IC50 value as CoRA concentration
increases is a direct measure of synergistic activity. To
appreciate this reasoning, assume that maraviroc and the FIs
displayed additive activity. The probability of viral entry
(Pentry) in the presence of a single inhibitor can be modeled
as shown in Equation 1.
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Figure 2. Combinatorial activities of CoRA AMD3100 and FI C37 against
wild-type EnvHXB2 and the V549E mutant variant. A, schematic of the gp41
ectodomain depicting the binding site for C37 and the relative position of the
V549E substitution. B, AMD3100 titrations of wild-type (black) and V549E
mutant (red) Env. The measured IC50 values were 26 ⫾ 4.1 and 27 ⫾ 6.4 nM,
respectively. C, C37 titration of wild-type (black) and V549E mutant (red) Env
in the absence (filled symbols) and presence (open symbols) of 100 nM
AMD3100. Data have been renormalized to the level of infection in the
absence of C37 and the presence of AMD3100 (if any). D, IC50 values for wildtype and V549E mutant Env as a function of AMD3100 concentration. Note
that the following data have been repeated in subsequent figures for comparative purposes: AMD3100 titration of wild-type EnvHXB2 (black squares in B,
repeated in Figs. 4B, 5B, and 7C); C37 titration of wild-type EnvHXB2 (black
squares in C, repeated in Fig. 7D); C37 IC50 values for wild-type EnvHXB2 as a
function of AMD3100 concentration (black squares in D, repeated in Fig. 3A as
green squares and in Fig. 7E as black squares); C37 IC50 values for the V549E
EnvHXB2 mutant variant as a function of AMD3100 concentration (red circles
in D, repeated in Fig. 3B as green squares).

reduced synergistic activities in combination with AMD3100.
For C37W628A, FI IC50 improved only 2.5-fold in the presence of
high concentrations of AMD3100 (compared with 7.4-fold for
wild-type C37). For C37N656D, the presence of AMD3100 did
not alter FI IC50 even at high CoRA concentrations.
Combined, the data suggested that reducing C-peptidebinding affinity decreased the magnitude of FI-CoRA synergy.
We next asked whether the converse was true. Did increasing
C-peptide affinity result in greater synergistic activity of this
drug combination? We employed two additional C37 variants
with enhanced affinity, C37-KYI (16-fold higher) and di-C37
(greater than 100-fold higher) (38). Against wild-type Env, the
enhanced binding affinity did not translate to higher potency
compared with C37, consistent with a kinetic restriction on
their inhibition (Table 1 and Fig. 3A) (see below and Ref. 38).
Moreover, C37-KYI and di-C37 displayed synergy with
AMD3100 that mimicked AMD3100/C37 synergy against wildtype Env in terms of magnitude and CoRA dependence. By
contrast, the enhancement of FI affinity significantly impacted
inhibition of the V549E Env variant (Table 1 and Fig. 3B). On
the one hand, C37-KYI potency was improved almost 20-fold,
but it still showed the same additive activity as C37 in combination with AMD3100. On the other hand, di-C37 potency was
improved ⬃100-fold and showed substantial synergy in combination with the CoRA. In fact, the potency of di-C37 and the
magnitude and CoRA dependence of AMD3100/di-C37 syn-

ergy were nearly identical for the wild-type and the V549E Env
variants. Thus, CoRA/C-peptide synergy was restored for an
Env variant with an affinity-disrupting mutation by sufficiently
dialing up the binding strength of the FI. The data implied that
CoRA/C-peptide synergy required a high-affinity interaction
between the C-peptide and gp41.
Modeling the impact of CoRA on C-peptide inhibition
Our data indicated that the antiviral activity of CoRA/C-peptide combinations depended on the affinity of C-peptide interactions. We previously showed that the factors determining
C-peptide potency differed for high and low-affinity inhibitors.
The discrepancy was best appreciated by modeling intermediate state inhibition as shown in Fig. 3C. Here, N, I, and F represent the native, intermediate, and fusogenic conformations. Fusion inhibitors (X) bind the intermediate state (IX)
and promote transition into an irreversibly deactivated state
(D). Rate constants kf and ks describe the N 3 F and IX 3 D
transitions, respectively, whereas kon and koff denote inhibitor association and dissociation from gp41. Based on this
model, Equation 4 for fusion inhibitor IC50 was derived (19).
IC50 ⫽

冉

冊

kf
koff
kf
kf
1⫹
⫽
⫹ KD
kon
ks
kon
ks

(Eq. 4)

For high-affinity and slowly dissociating FIs (koff ⬍⬍ ks),
inhibitor binding almost always leads to deactivation. In this
case, inhibitory potency is determined primarily by how fast the
J. Biol. Chem. (2017) 292(40) 16498 –16510
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Figure 3. Dependence of AMD3100/C37 synergy on C37-binding affinity. A and B, FI IC50 values for wild-type EnvHXB2 (A) and V549E mutant Env (B) are
plotted as a function of AMD3100 concentration. In order of increasing binding affinity, the C37 variants were C37N656D (black), C37W628A (red), C37 (wild-type,
green), C37-KYI (blue), and di-C37 (cyan). C, schematic depiction of intermediate-state inhibition by C37 and other FIs. States and rate constants are defined in
the text.

inhibitor can associate during the lifetime of the intermediate
state: IC50 ⬇ kf/kon. This kinetic dependence explains why C37,
C37-KYI, and di-C37 displayed the same potency against wildtype Env despite having widely varying binding affinities (Fig.
3A). In the proposed mechanism of synergy, CoRAs reduce the
level of coreceptors capable of interacting with Env, thereby
prolonging the intermediate state and increasing the chance of
FI binding gp41. Quantitatively, this proposed effect describes a
decrease in rate constant kf, which, in turn, results in a lower
IC50 value for high-affinity C-peptides.
For low-affinity, rapidly dissociating FIs (koff ⬎⬎ ks), inhibitor
association is most often followed by multiple cycles of dissociation and re-association before Env transitions into the fusogenic (F) or deactivated (D) state. Therefore, inhibitory potency
depends upon binding affinity and the relative difference
between the rates to states F and D: IC50 ⬇ (kf/ks)KD. The dependence of potency on binding affinity explains the difference in
IC50 values for C37, C37-KYI, and di-C37 against the V549E
Env variant (Fig. 3B). Our previous work has suggested that the
rates kf and ks for C-peptides share the same dependence on
cellular coreceptor levels (38).3 Thus, adding CoRA should
induce the same fold-reduction in kf and ks, leaving their ratio
unaltered and the IC50 values for the low-affinity, rapidly dissociating C-peptides unchanged. Hence, we propose that the sim3

It is not known why rate constant ks for C-peptide inhibitors depends upon
chemokine receptor levels on target cells. We have previously speculated
(38) that the IX 3 D transition follows the same conformational change as
the I 3 F transition, except that the attached C-peptide prevents proper
formation of the TOH, leading to irreversible misfolding of the gp41 ectodomain. This hypothesis predicts that ks and kf for C-peptide inhibitors
would share the same dependence on target cell chemokine receptor levels, as is observed.

16502 J. Biol. Chem. (2017) 292(40) 16498 –16510

ilar dependence of the I 3 F and Ix 3 D transitions on cellular
coreceptor levels leads to additive activity for combinations of
CoRAs and low-affinity C-peptides.
Preservation of CoRA/5-Helix synergy under low-affinity 5Helix interactions
Although both C-peptides and 5-Helix target gp41 during
the PHI, our previous work showed that these two inhibitor
classes induced Env deactivation through different mechanisms (38). Notably, the deactivation rate constant ks for 5-Helix inhibition did not depend on cellular coreceptor levels.
Therefore, we predicted that CoRA/5-Helix synergy should be
largely independent of 5-Helix-binding affinity. We tested this
prediction using EnvHXB2 variants with C-HR mutations N656S
and N656D, which reduced 5-Helix-binding affinity 30- and
5000-fold, respectively (Fig. 4A and Table 1) (38). All three Env
variants showed the same sensitivity to AMD3100, indicating
the C-HR substitutions did not impact CXCR4 utilization of
EnvHXB2 (Fig. 4B). We first used the wild-type version of 5-Helix (5HWT), an extremely high-affinity fusion inhibitor with
kinetically restricted potency (IC50 ⬇ kf/kon) against the wildtype and N656S Env variants and near kinetically restricted
potency against the N656D Env variant (Table 1 and Fig. 4, C
and E). As expected, the potency of 5HWT was not altered by
affinity-disrupting mutations in the C-HR region. Moreover,
IC50 values for 5HWT decreased upon addition of AMD3100,
consistent with a CoRA-dependent increase in the temporal
exposure of the gp41 C-HR region (Fig. 4E).
Next, we used a mutant variant of 5-Helix (5HLAVA) containing the L556A/V570A dual substitution that reduces the inhibitor-binding affinity 13,000-fold (19). 5HLAVA binds relatively
weakly to wild-type Env and even more poorly to the N656S and
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Figure 4. Maintenance of AMD3100/5-Helix synergy across a wide range
of 5-Helix binding affinities. A, schematic of the gp41 ectodomain depicting the 5-Helix-binding site and relative position of the N656S and N656D
substitutions. B, AMD3100 titrations of wild-type (black), N656S (red), and
N656D (green) EnvHXB2 variants. The measured IC50 values were 26 ⫾ 4.1, 19 ⫾
2.9, and 21 ⫾ 5.5 nM, respectively. C and D, 5HWT (C) and 5HLAVA (D) titrations
of the N656S Env variant in the absence (square) and presence of AMD3100 at
25 (circle), 50 (up triangle), and 100 nM (down triangle). Data have been normalized to the infectivity level in the absence of either inhibitor. E and F, IC50
values for 5HWT (E) and 5HLAVA (F) as a function of AMD3100 concentration for
wild-type (black), N656S (red), and N656D (green) Env. G, relative infectivity
levels of N656D mutant Env in the absence (square) or presence of AMD3100
at 50 (up triangle) or 100 nM (down triangle) in the presence of the indicated
concentrations of 5HLAVA. Data have been normalized to the level of infectivity in the presence of AMD3100 and absence of 5HLAVA. Note that the following data have been repeated in subsequent figures for comparative purposes: 5HWT IC50 values for wild-type EnvHXB2 as a function of AMD3100
concentration (black squares in E, repeated in Figs. 5C and 7F).

N656D Env variants (Table 1). Importantly, the rate of 5HLAVA
dissociation from the mutant Env variants substantially exceeds
the estimated rate of 5-Helix-induced gp41 deactivation
(koff ⬎⬎ ks, see Table 1). As expected for such a low-affinity FI,
5HLAVA potency depended on its binding affinity (IC50 ⬇ (kf/
ks)KD, see Table 1). The IC50 value was lowest against wild-type
Env (110 nM), higher against the intermediate-affinity variant
N656S Env (1000 nM), and highest against the most affinity-

Impact of kf-altering gp41 mutations on CoRA/FI synergy
Certain gp41 mutations can influence the lifetime of the
intermediate state without incurring a substantial disruption to
FI-binding affinity (Fig. 5) (54, 55). The substitution L565Q in
the N-HR elicits a decrease in fusion rate that is manifested by a
10-fold increase in sensitivity to kinetically restricted FI 5HWT
(Table 1). By contrast, the dual substitution N637K/T639I in
the C-HR enhances fusion rate, resulting in a 10-fold decrease
in 5HWT sensitivity (Table 1). We questioned whether the
effects of these gp41 mutations were mediated, in part, through
altered coreceptor interactions and, if so, how that would
impact CoRA/FI synergy. The IC50 values for AMD3100
against L565Q Env and N637K/T639I Env were 63 and 17 nM,
respectively, not substantially different from the 26 nM IC50
value for wild-type Env (Fig. 5B). The data suggested that the
substitutions minimally impacted CXCR4 utilization. The two
mutant Env variants showed AMD3100/5HWT synergy of comparable magnitude and CoRA dependence as that for wild-type
Env (Fig. 5C). Similar results were observed for synergy
between AMD3100 and the kinetically restricted FIs di-C37
and PIE12 trimer4 (56) that target the gp41 N-HR region (Fig. 5,
D and E). Thus, our data suggested that these gp41 mutations
altered an intrinsic rate of gp41 folding that can be further modified extrinsically through coreceptor binding.
Dissecting the dependence of FI/CoRA synergy on coreceptor
binding
Close inspection of our synergy data revealed a tendency for
FI IC50 values to level off at high CoRA concentrations. The
result suggested a limit to the degree that rate constant kf could
be reduced by lowering the levels of available coreceptor on
target cells. Based on this observation, we predicted that the
magnitude of CoRA/FI synergy would be smaller on target cells
expressing lower levels of coreceptor. To test this prediction,
we employed HeLa-derived JC.53 and JC.10 target cells that

4

PIE12 is a D-amino acid peptide selected by mirror-image phage display that
binds a hydrophobic pocket at the C terminus of the N-HR coiled coil (56).
In the PIE12 trimer, three PIE12 peptides are cross-linked using polyethylene glycol linkers to create a molecule capable of multivalent binding to
the gp41 N-HR region exposed during the PHI.
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disrupted variant N656D Env (⬎3000 nM). Despite interacting
with low affinity, 5HLAVA showed synergistic activity against all
three Env variants. Against the wild-type and N656S Env variants, the magnitude and CoRA dependence of the AMD3100/
5HLAVA synergy closely mimicked those for AMD3100/5HWT
synergy (compare Fig. 4, E and F). The low potency of 5HLAVA
against the N656D Env variant precluded accurate determination of IC50 values for a similar analysis. However, N656D Env
was substantially more sensitive to 1000 nM 5HLAVA in the presence of AMD3100 (50 and 100 nM) than in its absence (Fig. 4G).
Thus, the synergy between AMD3100 and 5-Helix was not significantly influenced by 5-Helix-binding affinity, even when the
rate of inhibitor dissociation exceeded the rate of gp41 deactivation. These results were consistent with the 5-Helix-induced
deactivation rate constant ks being independent of coreceptor
levels on target cells.
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Figure 5. Impact of rate-altering gp41 mutations on CoRA/FI synergy. A, schematic of the gp41 ectodomain depicting the di-C37-, PIE12 trimer-, and
5-Helix-binding sites and the relative positions of the L565Q and N637K/T639I substitutions. The three inhibitors bind with extremely high affinity and have
kinetically restricted inhibitory potencies. The L565Q substitution minimally disrupts on C37-binding affinity but significantly prolongs the PHI lifetime. The
N637K/T639I substitution actually increases 5-Helix-binding affinity and shortens N-HR exposure modestly and C-HR exposure significantly. B, AMD3100
titration of wild-type (black), L565Q (green), and N637K/T639I (red) EnvHXB2 variants. The measured IC50 values were 26 ⫾ 4.1, 63 ⫾ 1.2, and 17 ⫾ 6 nM,
respectively. C–E, IC50 values for 5HWT (C), di-C37 (D), and PIE12 trimer (E) as a function of AMD3100 concentration for the three Env variants.

have similar levels of CD4 (4 ⫻ 105 per cell) but different levels
of CCR5 (1.3 ⫻ 105 and 2.0 ⫻ 103 per cell, respectively) (57).
The IC50 value of CCR5 antagonist TAK-779 against HIV-1
pseudotyped with EnvBaL was lower on target cells expressing
lower CCR5 levels (JC.10), consistent with previous conclusions that CoRAs competitively block chemokine receptor
interactions with Env (Fig. 6A) (35, 39). Furthermore, the IC50
value for kinetically restricted FI C37 was significantly lower on
JC.10 cells compared with JC.53 cells, as expected for reduced
CCR5 levels leading to a decreased rate constant kf (Fig. 6B)
(38). As predicted, CoRA/FI synergy differed between the two
cell lines. For cells with high CCR5 levels (JC.53), FI IC50 values
decreased significantly (3–5-fold) in the presence of CoRA (Fig.
6, C and E). By contrast, for target cells with low levels of CCR5
(JC.10), FI IC50 values showed minimal dependence (less than
2-fold) on CoRA concentrations (Fig. 6, D and E). This difference between cell lines was not dependent on FI target site
(N-HR for C37 and C-HR for 5HWT) and was observed for both
laboratory-adapted (BaL, H5) and primary isolate (JRFL) Env
strains (Fig. 6, E–H). Thus, FI/CoRA synergy appeared to
require a sufficient level of chemokine receptors on target cells,
below which inhibitor combinations behaved in an additive
manner.
One explanation for these observations is that the coreceptor
binding stoichiometry required for HIV-1 entry is less than the
stoichiometry required to observe CoRA/FI synergy. To test
this conjecture, we investigated the properties of Env trimers
that contained less than three coreceptor-binding sites. We
generated HIV-1 from cells coexpressing wild-type EnvHXB2
(denoted H4) and a variant EnvHXB2 with a V3-loop from the
CCR5-tropic EnvSF162 (denoted H5) (58). The V3-loop swap
rendered H5 Env unable to mediate efficient viral entry on
CXCR4⫹ target cells but capable of mediating robust fusion on
CCR5⫹ cells. Coexpression of the two Env variants resulted in
four trimeric species, (H4)3, (H4)2(H5), (H4)(H5)2, and (H5)3,
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with the heterotrimers having a mixture of competent CXCR4and CCR5-binding sites (Fig. 7A). To specifically focus on heterotrimer activity, H4/H5 expression was biased 1:19, and the
resulting HIV-1 sample was applied to CXCR4⫹ cells (Fig. 7B).
With this expression ratio, the predominant trimeric species,
homotrimer (H5)3, lacked a CXCR4-binding site and was not
fusogenic. The other homotrimer, (H4)3, was fusogenic but
formed only a miniscule fraction of total Env trimers. The infectivity of this viral sample far exceeded the level predicted if only
homotrimeric (H4)3 contributed to membrane fusion (Fig. 7B).
The result suggested that the heterotrimeric Envs containing
either one or two CXCR4-binding sites were the predominant
fusogenic species in this viral population.
HIV-1 pseudotyped with H4/H5 ⫽ 1:19 displayed significantly higher sensitivity to both AMD3100 and C37 compared
HIV-1 pseudotyped with (H4)3 homotrimers alone (Fig. 7, C
and D). The results confirmed that Env heterotrimers contributed the majority of fusogenic activity in these mixed trimer
viral samples. The enhanced sensitivity to AMD3100 likely
reflected an increased requirement for CXCR4 on target cells to
compensate for a reduced number of coreceptor-binding sites
on fusogenic Env heterotrimers. The enhanced sensitivity to
C37 probably resulted from slower fusion kinetics due to
reduced coreceptor binding (similar to the impact of decreasing
coreceptor levels on target cells). Notably, C37 IC50 for HIV-1
pseudotyped with H4/H5 ⫽ 1:19 showed no dependence on
AMD3100 concentration (Fig. 7E). Likewise, 5HWT IC50
against this viral population was minimally perturbed in the
presence of AMD3100 (Fig. 7F). The results were in sharp contrast to the CoRA/FI synergy seen for HIV-1 pseudotyped with
(H4)3 homotrimers.
We repeated these experiments biasing H4/H5 expression
19:1 and using CCR5⫹ target cells (Fig. 8A). Again, the infectivity of viral samples containing mixed Env trimers exceeded that
predicted if only (H5)3 homotrimers contributed to viral entry
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Figure 6. Impact of target cell chemokine receptor levels on CoRA/FI synergy. A, titration of CoRA TAK-779 against EnvBaL-mediated HIV-1 entry into
JC.53 (high CCR5, filled squares) and JC.10 (low CCR5, open squares) target
cells. The measured IC50 values were 59 ⫾ 3.4 and 3.3 ⫾ 0.31 nM, respectively.
B, C37 titration of EnvBaL on the two cell lines. The measured IC50 values were
15 ⫾ 2.6 and 1.3 ⫾ 0.15 nM, respectively. C, C37 titrations of EnvBaL on JC.53
target cells (high CCR5) performed in the absence (black) and presence of 25
(red), 50 (green), and 100 nM (blue) TAK-779. D, C37 titrations of EnvBaL on JC.10
target cells (low CCR5) performed in the absence (black) and presence of 2.5
(red), 5 (green), and 10 nM (blue) TAK-779. E and F, IC50 values for C37 (E) and
5HWT (F) as a function of TAK-779 concentration for EnvBaL on JC.53 (high
CCR5, filled squares) and JC.10 (low CCR5, open squares). G and H, C37 IC50
values as a function of TAK-779 concentration for EnvJRFL (G) and EnvH5 (H) on
the two cell lines.

(Fig. 8B). Although expression of mixed trimers did not impact
TAK-779 sensitivity, HIV-1 containing heterotrimers was
much more sensitive to FI than HIV-1 expressing only (H5)3
homotrimers (Fig. 8, C and D). As before, the CoRA/FI synergy
observed for (H5)3 homotrimers was largely absent when heterotrimers were the predominant fusogenic Env species (Fig. 8,
E and F). Thus, regardless of which chemokine receptor was
used for entry, reducing the number of coreceptor-binding sites
on the Env trimer appeared to ablate the CoRA/FI synergy. The
data supported our conjecture that CoRA/FI synergy required
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Figure 7. Impact of modifying the number of CXCR4-binding sites per
EnvHXB2 trimer on CoRA/FI synergy. A, mixed trimer population resulting
from the coexpresssion of Env variants H4 (HXB2) and H5 in virus-producing
cells. Each of the four possible trimeric species has a different number of
competent CXCR4-binding sites (#). The fraction of each trimeric species
expressed in the entire HIV-1 sample is listed for H4/H5 expression ratios 1:0,
1:19, and 0:1. Numbers in the 1:19 column reflect binomial probabilities that
assume random assortment of individual protomers into the designated
trimer. B, relative infectivities of the 1:0, 1:19, and 0:1 HIV-1 samples applied to
U87.CD4.CXCR4 target cells. Viral input was normalized to p24 content of
each sample. The dotted lines in the 1:19 viral data reflect the relative fractions
of the trimeric species plotted on the same relative infectivity scale (blue,
(H5)3; green, (H5)2(H4); cyan, (H5)(H4)2; and black, (H4)3). The red line in the 0:1
viral data reflects the detection limit for viral infection in this set of experiments. The Western blots show the total expression of gp160 (*) and gp41 (**)
in HIV-1-producing cells expressing H4/H5 at the ratios indicated on the axis
of the plot above. The numbers to the left reflect molecular mass standards in
kDa. C and D, titrations of AMD3100 (C) and C37 (D) against the 1:0 (black) and
1:19 (red) viral samples. The AMD3100 IC50 values were 26 ⫾ 4.1 and 7.1 ⫾
0.77 nM, respectively. The C37 IC50 values were 2.8 ⫾ 0.27 and 0.70 ⫾ 0.16 nM,
respectively. E and F, IC50 values for C37 (E) and 5HWT (F) as a function of
AMD3100 concentration for the two HIV-1 samples.

multiple coreceptor binding events that exceeded the number
required for viral entry.

Discussion
Synergistic drug combinations provide opportunities for
therapeutic augmentation without requiring dose escalations
that increase both cost and potential toxicity risks. Synergistic
activity arises from drug interactions that can occur at microscopic to macroscopic scales, ranging from a single macromolJ. Biol. Chem. (2017) 292(40) 16498 –16510
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ecule (e.g. cooperative binding through allostery), to the cell or
tissue level (e.g. coordinated disruption of multi-protein signaling pathway), and to the whole organism (e.g. enhanced bioavailability of an active drug due to reduced in vivo clearance
caused by a second drug) (59). Mechanistic studies of drug
combinations can provide detailed insights into complex multistep biochemical processes. Here, we dissected the complicated synergy profile of two classes of HIV-1 entry inhibitors,
CoRAs that block gp120 – chemokine receptor interactions and
FIs that disrupt conformational transitions in gp41. The data
supported the proposed model that synergy for these inhibitors
reflects kinetic properties of Env conformational changes.
However, our results showed an unanticipated dependence of
synergy on coreceptor-binding stoichiometry and FI-binding
affinity.
In previous drug combination studies employing molecules
that disrupt gp120 – coreceptor interactions and C-peptide
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Figure 8. Impact of modifying the number of CCR5-binding sites per
EnvH5 trimer on CoRA/FI synergy. Data are presented as in Fig. 7 except that
the experiments utilized U87.CD4.CCR5 cells, TAK-779 as the CoRA, and an
H4/H5 expression ratio of 19:1 for the viral sample with mixed Env trimers. A,
the number of CCR5-binding sites (column #) and relative population of each
trimer species. B, infectivities of the 1:0, 19:1, and 0:1 HIV-1 samples and Env
expression levels in virus-producing cells. C and D, titrations of TAK-779 (C)
and C37 (D) against the 1:0 (black) and 19:1 (red) viral samples. TAK-779 IC50
values were 17 ⫾ 4.5 and 27 ⫾ 6.2 nM, respectively. C37 IC50 values in the
absence of CoRA were 7.9 ⫾ 2.6 and 1.0 ⫾ 0.32 nM, respectively. E and F, IC50
values for C37 (E) and 5HWT (F) as a function of TAK779 concentration for the
two HIV-1 samples.

T20, synergy was not consistently observed (31, 43– 47). Our
findings pointed to several possible explanations for this variability. First, we showed that CoRA/FI synergy critically
depended on levels of chemokine receptors on target cells, and
below some threshold, CoRAs and FIs interacted additively.
Discrepancies in chemokine receptor level among different cell
lines or among PBMC donors could account for the variance
between studies. Second, we demonstrated that the magnitude
of synergy between CoRAs and C-peptides like T20 depended
on C-peptide-binding affinity, with maximal synergy observed
for very high-affinity C-peptide variants, whereas mere additivity was measured for low-affinity C-peptide variants. With T20
having only a modest affinity for gp41 (52), discrepancies in the
N-HR sequences of Envs used in different studies could be a
source of variability. Finally, we determined that the number of
coreceptor binding events required for CoRA/FI synergy
exceeded the number required for HIV-1 entry. As differences
in gp120-chemokine receptor affinity could alter the coreceptor stoichiometry required for entry, we hypothesize that gp120
sequence variation among Envs used in these studies could
impact the level of observed synergy. Further work will be
needed to test this conjecture, but the mechanism might be
particularly relevant for understanding the wide variety of synergy profiles for clinical HIV-1 isolates in the aforementioned
SCH-C/T20 combination study (47).
Our results showed that the level of C37 resistance conferred
by the V549E substitution depended on CoRA concentration.
The V549E mutation reduced C37 potency 100-fold in the
absence of CoRA and 750-fold in the presence of 100 nM
AMD3100 (Fig. 2D). The result was surprising because the
escape mutation influenced FI interaction independently of
coreceptor binding. The impact of CoRAs on C37 resistance
was traced to disparities in the biophysical determinants of
potency for high- and low-affinity FIs (as distinguished by their
rates of dissociation relative to the rate of gp41 deactivation).
Although the IC50 values for high-affinity (slowly dissociating)
FIs depended upon the I 3 F transition rate (kf, see Fig. 3C),
IC50 values of low-affinity (rapidly dissociating) FIs depended
upon the ratio of the I 3 F and IX 3 D transition rates (kf/ks). FI
potency was enhanced by a CoRA-dependent decrease in kf.
However, that effect was mitigated for low-affinity C37 variants
because both kf and ks have the same dependence on target-cell
coreceptor levels for inhibitors targeting the gp41 N-HR. This
switch in determinants for C37 potency accounted for the loss
of CoRA/FI synergy in the setting of affinity-disrupting escape
mutations. This loss nullifies a potentially important benefit of
synergistic antiviral combinations, specifically the possibility
that inhibitor concentrations might be maintained in a useful
therapeutic window even when resistance mutations would
render one inhibitor poorly efficacious in the absence of a synergistic partner. Curiously, CoRA/FI synergy persisted for lowaffinity 5-Helix variants. The results reinforced the idea that
N-HR-targeted and C-HR-targeted FIs trigger irreversible gp41
deactivation (IX 3 D transition) through very different mechanisms (38).
In addition to gp120-coreceptor interactions, substitutions
in the gp41 N-HR and C-HR regions can influence the lifetime
of the PHI (54, 55). How such mutations impact the fusion

Complex synergy mechanisms of HIV-1 entry inhibitors
Experimental procedures
Cell lines and reagents
The following cell lines and reagents were obtained through
the AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, National Institutes of Health: U87.CD4.CXCR4
and U87.CD4.CCR5 cells from Drs. HongKui Deng and Dan
Littman (63); Chessie 8 hybridoma from Dr. George Lewis (64);
maraviroc (11580) (65, 66); AMD-3100 (67, 68); and TAK779
(69). HEK 293T cells were obtained from the ATCC. JC.53 and
JC.10 cells were kindly provided by Dr. David Kabat (Oregon
Health Sciences University) (57). PIE12 fusion inhibitors were
kindly provided by Dr. Michael Kay (University of Utah) (56).
Fusion inhibitor preparation
C-peptide T20 was synthesized using standard Fmoc (N-(9fluorenyl)methoxycarbonyl) chemistry by the Peptide Synthesis Facility at the Sidney Kimmel Cancer Center, Thomas Jefferson University. Cleaved, desalted peptides were purified to
homogeneity by reverse phase-HPLC using a Vydac C18 column and a linear gradient of acetonitrile in water containing
0.1% trifluoroacetic acid. C-peptide C37 and its variants were
prepared from a recombinant gp41 TOH construct NC1 as
described previously (28, 38). Briefly, NC1 was recombinantly
expressed and purified from bacterial lysates by metal-chelate
chromatography and subsequently subjected to trypsin
digestion to cleave C37 from the N-HR peptide N40. C37 was
purified to homogeneity using reverse phase-HPLC as
described above. Di-C37 is a dimerized form of C37 connected via an engineered disulfide bond at the C terminus of
each monomer (38).
5-Helix proteins contain three N40 segments and two C37
segments alternately connected by short linkers into a single
polypeptide (28). The proteins were recombinantly expressed
and purified as described previously (19). Briefly, 5-Helix was
solubilized from bacterial inclusion bodies using 8 M guanidine
HCl in Tris-buffered saline (TBS), loaded onto nickel-nitrilotriacetic acid-agarose beads (Qiagen), and renatured in 4 M guanidine HCl by a reverse thermal gradient (90 °C to room temperature over 4 h). Aggregates were separated from properly
folded protein by size-exclusion chromatography (Superdex 75,
GE Healthcare).
The concentrations of T20, PIE12 trimer, C37 peptides, and
5-Helix proteins were determined by absorbance at 280 nm by
the method of Edelhoch (70). The interaction and inhibition
properties of these inhibitors have been extensively characterized (19, 38, 52, 56).
HIV-1 production and characterization
HIV-1 particles were prepared from 293T cells (5 ⫻ 106)
transfected (X-tremeGENE, Roche Applied Science) with 2.5
g of Env-deficient HIV-1NL4-3 genome pNL4-3R⫺E⫺Luc⫹
(71) and 2.5 g (total) of one or two Env-expressing plasmids
(pEBB_EnvX, X ⫽ HXB2, JR-FL, BaL, and H5). EnvH5 is an
EnvHXB2 variant with a V3 loop derived from CCR5-tropic
EnvSF162 (58). Virus-containing supernatants were harvested
48 h post-transfection and were used fresh for infectivity studies described below. Virus-producing cells were lysed and anaJ. Biol. Chem. (2017) 292(40) 16498 –16510
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rate is not known. Given the packing of gp120 around gp41 in
the native state (and possibly the PHI (58)), it is formally possible that gp41 substitutions could exert effects on gp120 structure and indirectly alter coreceptor utilization by Env. In this
study, the kf-altering substitutions L565Q and N637K/T639I
did not have a large impact on CoRA potency. Furthermore,
both the slower and faster Env variants showed the same synergy profile (both in magnitude and concentration dependence) as wild-type Env. Together, the data suggested that
these gp41 substitutions exerted minimal impact on coreceptor
utilization by Env. Instead, the results implied that the gp41
sequence sets a basal lifetime for the PHI (observed at high
CoRA concentrations) that can be shortened by excess coreceptor binding.
Our findings also offered insights into the timing of coreceptor binding events coordinating Env conformational changes.
In one model of HIV-1 entry, CD4 binding to the native state
drives Env into the PHI, whereas coreceptor binding during the
PHI triggers collapse into the TOH (60). This model explained
how coreceptor levels on target cells influence PHI lifetime and
FI potency. In support of this model, soluble CD4 (sCD4) alone
was shown to be sufficient to trigger Env to expose FI-binding
sites in gp41 pulldown and Env-mediated membrane fusion
assays (of note, these studies employed laboratory-adapted Env
strains prone to rapid and efficient sCD4-induced gp120 shedding) (17, 18, 20, 61, 62). However, the model failed to explain
the difference between CoRAs and FIs observed in time-ofaddition assays (37, 39). In these studies, escape from CoRA
inhibition occurred considerably before escape from FI inhibition, implying that coreceptor binding significantly preceded
collapse into the TOH. Our results showing an absence of
CoRA/FI synergy at low coreceptor-binding stoichiometry suggested a solution to this inconsistency; the first coreceptorbinding event precedes and facilitates transformation into the
PHI, whereas subsequent coreceptor binding events during the
PHI promote collapse into the TOH. Only the first coreceptor
binding event is absolutely required for HIV-1 entry, whereas
subsequent binding events primarily modulate the rate of
fusion. Env species mediating fusion meet only the minimal
coreceptor-binding requirement when coreceptor levels on
target cells are low or Env trimers contain one functional coreceptor-binding site. Because Env does not interact with additional coreceptors, the PHI lifetime remains unmodulated, and
FI potency becomes CoRA independent.
Based on the functionality of H4/H5 mixtures, our model
currently assumes that a single coreceptor binding event is sufficient to drive transformation into the PHI. However, the
model would remain valid if two coreceptor binding events
were required to facilitate this transition, and only the third
modulated the PHI lifetime. Indeed, results from this study suggest that different Env strains may have different coreceptorbinding requirements for entry (e.g. compare the fusogenic
activities of HIV-1 pseudotyped with H4/H5 mixtures in Figs.
7B and 8B). Future work with better defined Env heterotrimers
will be needed to piece together the exact stoichiometries of
coreceptor binding that facilitate the transition of Env into the
PHI and, ultimately, the TOH.
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lyzed by Western blotting for expression of Env. Briefly, lysates
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supernatants were determined by Bradford analysis (Thermo
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antibody Chessie 8, which recognizes an epitope in the gp160
and gp41 cytoplasmic tail (64). Western blottings were developed with an HRP-conjugated secondary antibody (Jackson
ImmunoResearch) and ECL reagent kit (Pierce).
HIV-1 infection was measured on U87 cells, except as noted
in Fig. 6. Cells were plated at a density of 20,000 per well in
48-well plates 18 –24 h prior to infection. On the day of infection, media were replaced with HIV-1-containing supernatant
(see above) and fresh media containing one or two inhibitors as
indicated. After 36 – 48 h, the cells were lysed in 1% Triton
X-100, and levels of the luciferase reporter were assessed by
luminescence (Promega or Pierce). To measure fusogenic
activities of HIV-1 particles pseudotyped with Env strain H4,
H5, or a mixture of H4 and H5 (Figs. 7B and 8B), luciferase
activity was normalized to p24 content of the viral sample
determined by ELISA (Aalto, Ireland).
Inhibitor titrations of viral infection were fit to the simple
dose-response Langmuir equation (Equation 1) to extract IC50
values. This choice was supported by the observation that the
vast majority of titrations (⬎97%) fit to the Hill equation with a
Hill coefficient nH between 0.9 and 1.1.
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